Morgan Stanley lowered the firm’s price target on Idexx Laboratories (IDXX) to $550 from $559 and keeps an Overweight rating on the shares. After having met with several Animal Health management teams at VMX, the world’s largest companion animal health conference, the analyst tells investors that “sentiment was cautious into 2025” on low compliance and deteriorating vet office visit trends. In light of foreign exchange dynamics and “a continuing lackluster vet visit backdrop,” the firm is trimming estimates and price targets for Idexx, Zoetis (ZTS) and Elanco (ELAN).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Zoetis price target lowered to $180 from $210 at Stifel
- Idexx Laboratories Approves Nonqualified Deferred Compensation Plan
- Idexx Laboratories announces 5M share increase in share repurchase pact
- Tesla upgraded, Autodesk initiated: Wall Street’s top analyst calls
- Idexx Laboratories initiated with an Outperform at Leerink